KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Dividends Paid - Common (2019 - 2025)

Royalty Pharma's Dividends Paid - Common history spans 6 years, with the latest figure at $40.8 million for Q4 2025.

  • For Q4 2025, Dividends Paid - Common rose 29.6% year-over-year to $40.8 million; the TTM value through Dec 2025 reached $157.1 million, up 25.48%, while the annual FY2025 figure was $167.5 million, 33.81% up from the prior year.
  • Dividends Paid - Common for Q4 2025 was $40.8 million at Royalty Pharma, down from $53.8 million in the prior quarter.
  • Across five years, Dividends Paid - Common topped out at $181.0 million in Q2 2022 and bottomed at -$230.2 million in Q4 2021.
  • The 5-year median for Dividends Paid - Common is $33.3 million (2022), against an average of $35.1 million.
  • The largest YoY upside for Dividends Paid - Common was 114.4% in 2022 against a maximum downside of 183.38% in 2022.
  • A 5-year view of Dividends Paid - Common shows it stood at -$230.2 million in 2021, then surged by 114.4% to $33.2 million in 2022, then fell by 7.91% to $30.5 million in 2023, then increased by 3.01% to $31.4 million in 2024, then rose by 29.6% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Dividends Paid - Common are $40.8 million (Q4 2025), $53.8 million (Q1 2025), and $31.4 million (Q4 2024).